Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy by Skvortsova, V.I. et al.
REVIEWS
  VOL. 10  № 4 (39)  2018  | ACTA NATURAE | 59
INTRODUCTION
Uncontrolled aggregation of certain proteins, with 
the formation of histopathological inclusions (pro-
teinopathy), is a major aspect of the pathogenesis of 
many neurodegenerative diseases (NDDs), including 
amyotrophic lateral sclerosis (ALS). Hence, the devel-
opment of drugs capable of inhibiting proteinopathy 
progression is considered as an important direction in 
the development of pathogenic therapy for NDDs. Data 
from recent studies, which have been independently 
obtained at various laboratories in different countries, 
have convincingly proved the ability of a drug that 
belongs to a gamma-carboline group – Dimebon (La-
trepirdine) – to effectively inhibit the progression of 
model proteinopathies in various transgenic animals. 
Our findings demonstrate the efficacy of Dimebon and 
its derivatives in inhibiting proteinopathy progression 
in model transgenic systems with a ALS phenotype.
Amyotrophic lateral sclerosis is a serious condition 
of the nervous system, with specific loss of motor neu-
rons, and it is a type of proteinopathy caused by the ag-
gregation of certain proteins. The association between 
pathogenic aggregation of these proteins and the de-
velopment of a ALS phenotype has been demonstrated 
in numerous experimental studies on the modeling of 
the main mechanisms of a neurodegenerative process 
affecting motor neurons [1–3]. In a histopathological 
analysis of idiopathic ALS, the autopsy material of 
most patients contains intracellular protein inclusions. 
Of particular interest are deposits formed by TDP-43 
and FUS DNA/RNA-binding proteins [4–6]. The direct 
mechanisms underlying the pathogenic aggregation 
of these proteins, leading to dysfunction and death of 
motor neurons, may be a specific trait of a given pro-
tein. There is little doubt that the process of pathogenic 
protein aggregation plays an important role in the 
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pathogenesis of all ALS forms and might be an obvious 
target for therapeutic interventions.
NEUROPROTECTIVE PROPERTIES 
OF GAMMA-CARBOLINES
Data from independent studies at several laboratories 
have demonstrated that compounds belonging to the 
gamma-carboline class are potential neuroprotective 
agents leading to reduced levels of pathogenic ag-
gregation and/or activating the intracellular defense 
mechanisms of controlled degradation of aggregated 
proteins [7, 8]. Initial findings for these gamma-car-
bolines properties were obtained in Dimebon stud-
ies showing a correction of the cognitive function in 
patients with Alzheimer’s disease (AD), which is the 
most common neurodegenerative disease in the pro-
teinopathy group [9, 10]. Furthermore, clinical trials 
conducted at several centers have revealed a positive 
effect from Dimebon on the cognitive function of pa-
tients with Huntington’s disease [11]. Yet, phase III 
clinical trials have indicated that Dimebon treatment is 
not considered effective compared to other developed 
drugs for the pathogenic therapy of AD [12], which is 
most likely due to the extremely high heterogeneity of 
nosological forms of Alzheimer’s disease. However, the 
mechanisms of action of the drug and its derivatives on 
proteinopathy progression have remained the object 
of intense research at several laboratories [13]. For ex-
ample, the results of a recent meta-analysis revealed 
a positive effect from Dimebon on neuropsychiatric 
status indicators in AD patients [14] and provided an 
additional incentive to continue research in this di-
rection. In addition, in a homogeneous model system 
of transgenic animals, Dimebon was shown to inhibit 
the development of tau proteinopathy, which is one 
of the key components of AD pathology [15]. Another 
key proteinopathy in the pathogenesis of AD is cere-
bral amyloidosis, which was also inhibited by Dimebon 
in TgCRND8 [16–18] and 3xTg-AD [19] mice, but not 
in a 5xFAD model characterized by a more aggres-
sive course of amyloidosis [20]. These data served as 
grounds for expanding the range of research areas of 
gamma-carbolines effects on the progression of oth-
er proteinopathies that play an important role in the 
pathogenesis of neurodegenerative diseases.
EFFECT OF GAMMA-CARBOLINES ON THE 
PROGRESSION OF PROTEINOPATHIES ASSOCIATED WITH 
THE SPECIFIC INVOLVEMENT OF MOTOR NEURONS
Chronic administration of Dimebon to a transgenic 
mouse model with the pan-neuronal expression of 
gamma-synuclein which reproduced the main features 
of ALS pathogenesis [21, 22] delayed the progression of 
proteinopathy [23, 24]. In this case, there was a signifi-
cant decrease in the level of aggregated detergent-in-
soluble gamma-synuclein isoforms in affected areas 
of the nervous system in transgenic mice [25] and a 
decrease in gamma-synuclein-reactive inclusions in the 
affected spinal cord parts of the experimental animals 
[21, 22]. This effect was more pronounced if administra-
tion was begun at the pre-symptomatic stage, long be-
fore the first manifestations of the pathological process, 
according to both clinical symptoms and histological 
analysis. The same feature of Dimebon was observed 
in SOD1G93A transgenic mice: if Dimebon was adminis-
tered long before the expected age of manifestations of 
ALS phenotype-associated symptoms, then the onset 
of model disease symptoms occurred later, leading to 
an increased lifespan for the animals [26]. However, if 
Dimebon administration was started at an age closer 
to the expected onset of model disease symptoms, then 
the drug effects were much less pronounced [27]. We 
confirmed the ability of Dimebon and its derivatives to 
inhibit proteinopathy progression in a FUS1-359 trans-
genic mouse line [28, 29] which was recently generated 
and represents an adequate model of specific involve-
ment of motor neurons with the ALS phenotype. In the 
nervous system of these mice, similarly to patients with 
FUS-associated forms of ALS, the histopathological 
analysis reveals an accumulation of aberrant FUS iso-
forms in characteristic cytoplasmic protein aggregates. 
Both Dimebon and its derivatives could modify, albeit 
with different efficacies, the progression of FUS pro-
teinopathy in the nervous system of the FUS1-359 mice 
[30]. For example, the lifespan of model animals treated 
with Dimebon increased statistically significantly. Fur-
thermore, transfer of the FUS1-359 mouse line from the 
C57Bl/6J genetic background, which was initially used 
in most studies in various laboratories, to the CD-1 ge-
netic background did not affect the proteinopathy-in-
hibiting effect of gamma-carbolines and may not be 
explained by increased sensitivity of the C57Bl/6J line 
to gamma-carbolines [30]. In addition to an increased 
lifespan, the FUS1-359 mice treated with Dimebon or its 
derivative were characterized by a delayed onset of 
model disease symptoms with the development of a 
pronounced ALS phenotype if administration of the 
compounds was initiated at early latent stages of FUS 
proteinopathy [31]. However, the exact mechanism 
of Dimebon action remains unclear. The existing data 
from biochemical studies, as well as experiments on cell 
cultures and animals, suggest that Dimebon is a mul-
titarget drug capable of affecting many intracellular 
processes and various pathogenic pathways in neurons 
and other cells affected by neurodegenerative changes 
[7].
Particularly, Dimebon can modulate the functioning 
of receptors and channels, change the kinetics of sig-
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naling enzymes [9, 32–35], as well as stabilize mitochon-
drial activity [36, 37]. But perhaps, the most significant 
property of Dimebon, which makes it a basic compound 
in the development of approaches for the treatment of 
proteinopathy, lies in its ability to inhibit the accumu-
lation of cellular pathogenic protein aggregates.
GAMMA-CARBOLINE-BASED INHIBITION OF 
ACCUMULATION OF PATHOHISTOLOGICAL 
PROTEIN INCLUSIONS IN NEURONAL CYTOPLASM
The ability of Dimebon to prevent an accumulation 
of pathogenic protein inclusions in neuronal bodies 
was first demonstrated in our joint research with 
M. Hasegawa’s and M. Goedert’s laboratories on cell 
cultures producing the aberrant and highly aggre-
gating RNA-binding protein TDP-43 [38, 39]. The 
effect was confirmed using another cell model with 
the aggregation of the RNA-binding protein FUS. We 
demonstrated that addition of Dimebon and/or its de-
rivatives to cultured human neuroblastoma cells with 
FUS proteinopathy reduces both the amount of insol-
uble protein forms in the cytoplasmic fraction and the 
amount of protein inclusions formed in the cytoplasm 
(unpublished data). Subsequent studies performed 
on various model proteinopathy systems confirmed 
these effects, and in our view they are associated with 
the activation of the autophagosome system in Dime-
bon-treated groups [16, 40–42].
CONCLUSION
The results of a decade-long research effort conducted 
at leading Russian and international laboratories have 
demonstrated that compounds from the gamma-car-
boline series are indeed capable of suppressing the 
progression of certain types of proteinopathies and, as 
in the case of ALS models, slow down the development 
of the model phenotype of neurodegenerative process-
es in vivo. It is the modulation of aggregation of the 
proteins involved in proteinopathy mechanisms that is 
considered as the major element behind the concept of 
developing pathogenic therapy for neurodegenerative 
diseases [43]. At present, there is enough supporting 
evidence for considering Dimebon and its derivatives 
as promising compounds for the development of new 
therapeutic agents with improved pharmacokinetics 
and efficacy, which may be used as part of a complex 
pathogenic therapy for socially significant neurodegen-
erative diseases. 
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